Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given an average recommendation of “Buy” by the ten brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $21.29.

Several analysts recently commented on STOK shares. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, Chardan Capital initiated coverage on Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 price target for the company.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. This represents a 38.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter worth $124,000. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter worth about $160,000. The Manufacturers Life Insurance Company raised its holdings in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. purchased a new position in Stoke Therapeutics during the third quarter worth approximately $192,000. Finally, Rhumbline Advisers increased its position in shares of Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after buying an additional 2,787 shares in the last quarter.

Stoke Therapeutics Stock Performance

STOK stock opened at $10.99 on Friday. The company has a market capitalization of $582.14 million, a price-to-earnings ratio of -5.23 and a beta of 0.95. The business’s 50 day moving average price is $11.08 and its two-hundred day moving average price is $12.72. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Sell-side analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.